{"id":"https://openalex.org/W2115272811","doi":"https://doi.org/10.1158/1535-7163.mct-13-0692","title":"BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia","display_name":"BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia","publication_year":2013,"publication_date":"2013-10-03","ids":{"openalex":"https://openalex.org/W2115272811","doi":"https://doi.org/10.1158/1535-7163.mct-13-0692","mag":"2115272811","pmid":"https://pubmed.ncbi.nlm.nih.gov/24092807","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3881173"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-13-0692","doi":"https://doi.org/10.1158/1535-7163.mct-13-0692","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-13-0692","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3881173","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076024121","display_name":"William E. Pierceall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"William E. Pierceall","raw_affiliation_strings":["Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","Division of Cancer Medicine, Department of Leukemia","Molecular Hematology and Therapy, Department of Stem Cell Transplantation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Division of Cancer Medicine, Department of Leukemia","institution_ids":[]},{"raw_affiliation_string":"Molecular Hematology and Therapy, Department of Stem Cell Transplantation","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016607292","display_name":"Steven Mitchell Kornblau","orcid":"https://orcid.org/0000-0002-5990-9548","observed_orcids":["https://orcid.org/0000-0002-5990-9548"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven M. Kornblau","raw_affiliation_strings":["Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","Division of Cancer Medicine, Department of Leukemia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Division of Cancer Medicine, Department of Leukemia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055076896","display_name":"Nicole E. Carlson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole E. Carlson","raw_affiliation_strings":["Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","Division of Cancer Medicine, Department of Leukemia","Molecular Hematology and Therapy, Department of Stem Cell Transplantation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Division of Cancer Medicine, Department of Leukemia","institution_ids":[]},{"raw_affiliation_string":"Molecular Hematology and Therapy, Department of Stem Cell Transplantation","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057822243","display_name":"Xuelin Huang","orcid":"https://orcid.org/0000-0003-1192-9336","observed_orcids":["https://orcid.org/0000-0003-1192-9336"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xuelin Huang","raw_affiliation_strings":["Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","Division of Cancer Medicine, Department of Leukemia","Molecular Hematology and Therapy, Department of Stem Cell Transplantation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Division of Cancer Medicine, Department of Leukemia","institution_ids":[]},{"raw_affiliation_string":"Molecular Hematology and Therapy, Department of Stem Cell Transplantation","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005136176","display_name":"Noel Blake","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Noel Blake","raw_affiliation_strings":["Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","Division of Cancer Medicine, Department of Leukemia","Molecular Hematology and Therapy, Department of Stem Cell Transplantation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Division of Cancer Medicine, Department of Leukemia","institution_ids":[]},{"raw_affiliation_string":"Molecular Hematology and Therapy, Department of Stem Cell Transplantation","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058016010","display_name":"Ryan J. Lena","orcid":"https://orcid.org/0000-0003-1282-9492","observed_orcids":["https://orcid.org/0000-0003-1282-9492"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Lena","raw_affiliation_strings":["Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","Division of Cancer Medicine, Department of Leukemia","Molecular Hematology and Therapy, Department of Stem Cell Transplantation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Division of Cancer Medicine, Department of Leukemia","institution_ids":[]},{"raw_affiliation_string":"Molecular Hematology and Therapy, Department of Stem Cell Transplantation","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066765735","display_name":"Michael R. Elashoff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Elashoff","raw_affiliation_strings":["Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","Division of Cancer Medicine, Department of Leukemia","Molecular Hematology and Therapy, Department of Stem Cell Transplantation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Division of Cancer Medicine, Department of Leukemia","institution_ids":[]},{"raw_affiliation_string":"Molecular Hematology and Therapy, Department of Stem Cell Transplantation","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022647201","display_name":"Marina Y Konopleva","orcid":"https://orcid.org/0000-0002-9347-2212","observed_orcids":["https://orcid.org/0000-0002-9347-2212"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marina Konopleva","raw_affiliation_strings":["Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","Division of Cancer Medicine, Department of Leukemia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Division of Cancer Medicine, Department of Leukemia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052090140","display_name":"Michael H. Cardone","orcid":"https://orcid.org/0000-0001-6484-5473","observed_orcids":["https://orcid.org/0000-0001-6484-5473","https://orcid.org/0009-0001-0356-7681"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael H. Cardone","raw_affiliation_strings":["Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","Division of Cancer Medicine, Department of Leukemia","Molecular Hematology and Therapy, Department of Stem Cell Transplantation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Division of Cancer Medicine, Department of Leukemia","institution_ids":[]},{"raw_affiliation_string":"Molecular Hematology and Therapy, Department of Stem Cell Transplantation","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079262854","display_name":"Michael Andreeff","orcid":"https://orcid.org/0000-0002-1144-1958","observed_orcids":["https://orcid.org/0000-0002-1144-1958"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael Andreeff","raw_affiliation_strings":["Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","Division of Cancer Medicine, Department of Leukemia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Division of Cancer Medicine, Department of Leukemia","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5076024121","https://openalex.org/A5079262854"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":2.5554,"has_fulltext":false,"cited_by_count":33,"citation_normalized_percentile":{"value":0.90005035,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"12","issue":"12","first_page":"2940","last_page":"2949"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.005200000014156103,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9539999961853027},{"id":"https://openalex.org/keywords/bh3-profiling","display_name":"BH3 profiling","score":0.8629999756813049},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.8009999990463257},{"id":"https://openalex.org/keywords/building-information-modeling","display_name":"building information modeling","score":0.6620000004768372},{"id":"https://openalex.org/keywords/mitochondrial-membrane-depolarization","display_name":"mitochondrial depolarization","score":0.8230000138282776},{"id":"https://openalex.org/keywords/bcl-2-family-proteins","display_name":"Bcl-2 family proteins","score":0.9350000023841858},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.7850000262260437},{"id":"https://openalex.org/keywords/treatment-response-prediction","display_name":"treatment response prediction","score":0.7739999890327454},{"id":"https://openalex.org/keywords/cytogenetic-risk-stratification","display_name":"cytogenetic risk stratification","score":0.765999972820282},{"id":"https://openalex.org/keywords/patient-age","display_name":"patient age","score":0.6150000095367432},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8610000014305115},{"id":"https://openalex.org/keywords/event-free-survival","display_name":"event-free survival","score":0.9190000295639038},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7730000019073486}],"concepts":[{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.8713699579238892},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6693828105926514},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6368750929832458},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6084700226783752},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5939635038375854},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.5194451212882996},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.49750950932502747},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.49066412448883057},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.45279040932655334},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.43096500635147095},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3435187339782715},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.17239230871200562},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000072224","descriptor_name":"Bcl-2-Like Protein 11","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008565","descriptor_name":"Membrane Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010446","descriptor_name":"Peptide Fragments","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D011518","descriptor_name":"Proto-Oncogene Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012372","descriptor_name":"ROC Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051017","descriptor_name":"Apoptosis Regulatory Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1158/1535-7163.mct-13-0692","doi":"https://doi.org/10.1158/1535-7163.mct-13-0692","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-13-0692","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:24092807","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24092807","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:europepmc.org:2869931","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3881173","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3881173","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3881173","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Mol Cancer Ther","raw_type":"Text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.874.7616","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.874.7616","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/12/12/2940.full.pdf","raw_type":"text"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:2869931","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3881173","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[{"id":"https://openalex.org/G1402313056","display_name":"SPORE University of Texas M. D. Anderson Cancer Center-Leukemia","funder_award_id":"P50CA100632","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G3774884214","display_name":"THE THERAPY OF AML","funder_award_id":"P01CA055164","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G4916491104","display_name":null,"funder_award_id":"HHSN261201200039C","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G7396927615","display_name":null,"funder_award_id":"HHSN261201200039I","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000878657","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA016672","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W199589262","https://openalex.org/W1211118294","https://openalex.org/W1981438266","https://openalex.org/W2004361323","https://openalex.org/W2053904152","https://openalex.org/W2062087831","https://openalex.org/W2062301404","https://openalex.org/W2066880509","https://openalex.org/W2072778470","https://openalex.org/W2083086786","https://openalex.org/W2093917816","https://openalex.org/W2096695840","https://openalex.org/W2097007474","https://openalex.org/W2097290512","https://openalex.org/W2098265722","https://openalex.org/W2109912534","https://openalex.org/W2116177527","https://openalex.org/W2118691390","https://openalex.org/W2121301050","https://openalex.org/W2126983941","https://openalex.org/W2139638366","https://openalex.org/W2158216140","https://openalex.org/W2158294624","https://openalex.org/W2162700652","https://openalex.org/W2312674677","https://openalex.org/W2331137050","https://openalex.org/W4238492599"],"related_works":["https://openalex.org/W7095645596","https://openalex.org/W7099646390","https://openalex.org/W2598749276","https://openalex.org/W4244761909","https://openalex.org/W7096562014","https://openalex.org/W4415217298","https://openalex.org/W4404769006","https://openalex.org/W4409626263","https://openalex.org/W4405038592","https://openalex.org/W2496574993"],"abstract_inverted_index":{"As":[0],"acute":[1],"myelogenous":[2],"leukemia":[3],"(AML)":[4],"patient":[5,144,155,259],"response":[6,18,49,99],"to":[7,21,31,46,50,100],"cytarabine-based":[8,51],"standard-of-care":[9],"treatment":[10],"is":[11],"variable,":[12],"stratification":[13],"into":[14,232],"subgroups":[15],"by":[16,82,170,234,254],"biomarker-predicted":[17],"may":[19],"lead":[20],"improved":[22,138],"clinical":[23,48,212],"outcomes.":[24],"Here,":[25],"we":[26],"assess":[27],"cell":[28,63],"mitochondrial":[29],"depolarization":[30],"proapoptotic":[32],"signaling":[33],"BH3-only":[34],"peptides":[35],"as":[36],"a":[37,115],"surrogate":[38],"for":[39,140,177,258],"the":[40,243],"function":[41],"of":[42,206,210,246,252],"Bcl-2":[43],"family":[44],"proteins":[45],"address":[47],"therapy":[52],"in":[53,249],"patients":[54,75,167,229],"with":[55,76,89,98,114],"AML":[56,253],"(N":[57],"=":[58,110,123,131,147,161,181,184,192,195,220,226],"62).":[59],"Peripheral":[60],"blood":[61],"mononuclear":[62],"(PBMC)":[64],"or":[65],"bone":[66],"marrow":[67],"aspirate":[68],"specimens":[69],"were":[70,168,230],"obtained":[71],"from":[72],"newly":[73],"diagnosed":[74],"AML,":[77],"viably":[78],"preserved,":[79],"and":[80,152,189,222],"assayed":[81],"flow":[83],"cytometry":[84],"following":[85],"BH3":[86,91,247],"profile":[87,118],"assay":[88],"individual":[90],"peptides.":[92],"Mann-Whitney":[93],"analysis":[94,136],"indicates":[95,137],"biomarker":[96],"correlation":[97,215],"induction":[101],"therapy:":[102],"Notably,":[103],"BIM":[104,141,153,173,235],"priming":[105],"was":[106,175],"highly":[107],"significant":[108,176],"(P":[109,180,191,219,225],"2":[111,132],"\u00d7":[112,133],"10(-6))":[113],"compelling":[116],"sensitivity/specificity":[117],"[area":[119],"under":[120],"curve":[121],"(AUC)":[122],"0.83;":[124],"95%":[125,149,163,186,197],"confidence":[126],"interval":[127],"(CI),":[128],"0.73-0.94;":[129],"P":[130],"10(-10)].":[134],"Multivariate":[135],"profiles":[139],"readout":[142,174],"+":[143,154,157],"age":[145,156],"(AUC":[146,160],"0.89;":[148],"CI,":[150,164,187,198],"0.81-0.97)":[151],"cytogenetic":[158,171],"status":[159],"0.91;":[162],"0.83-0.98).":[165],"When":[166],"stratified":[169,231],"status,":[172],"both":[178],"intermediate":[179],"0.0017;":[182],"AUC":[183,194],"0.88;":[185],"0.71-1.04)":[188],"unfavorable":[190],"0.023;":[193],"0.79;":[196],"0.58-1.00)":[199],"risk":[200],"groups,":[201],"demonstrating":[202],"predictive":[203],"power":[204],"independent":[205],"cytogenetics.":[207],"Additional":[208],"analyses":[209],"secondary":[211],"endpoints":[213],"displayed":[214],"between":[216],"overall":[217],"survival":[218,224],"0.037)":[221],"event-free":[223],"0.044)":[227],"when":[228],"tertiles":[233],"peptide":[236],"response.":[237],"Taken":[238],"together,":[239],"these":[240],"results":[241],"highlight":[242],"potential":[244],"utility":[245],"profiling":[248],"personalized":[250],"diagnostics":[251],"offering":[255],"actionable":[256],"information":[257],"management":[260],"decisions.":[261]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":4}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}